Trump health chief renews call to end key drug-pricing tactic
HHS' Alex Azar told lawmakers that it may be time to eliminate the complex system of rebates that drug companies and pharmacy-benefit managers use to negotiate and set prices.
Pharmacy benefits
Benefits Think Employees need help in the hunt for cheaper prescriptions
A pharmacy benefit manager can often find true savings to critical drugs in the same neighborhood.
Heidi Rasmussen
Freshbenies
Benefits Think Employees need help in the hunt for cheaper prescriptions
A pharmacy benefit manager can often find true savings to critical drugs in the same neighborhood.
Heidi Rasmussen
Freshbenies
Benefits Think Why Trump’s drug plan fails employers
By not prioritizing the use of pharmacy benefit management drug rebates, the administration is hurting companies, who shoulder the burden of rising costs by all stakeholders in the supply chain.
Cheryl Larson
Midwest Business Group on Health
Benefits Think Why Trump’s drug plan fails employers
By not prioritizing the use of pharmacy benefit management drug rebates, the administration is hurting companies, who shoulder the burden of rising costs by all stakeholders in the supply chain.
Cheryl Larson
Midwest Business Group on Health
Trump drug speech to propose more competition to lower costs
The president will propose a sweeping effort to bring down U.S. drug prices in a plan to make good on a campaign promise.
Benefits Think A pharmacist looks at the evolving pharmacy benefit space
The price of prescriptions has skyrocketed and the industry needs to address matters sooner rather than later.
Zack Pace
CBIZ
Benefits Think A pharmacist looks at the evolving pharmacy benefit space
The price of prescriptions has skyrocketed and the industry needs to address matters sooner rather than later.
Zack Pace
CBIZ
Benefits Think The role of PBMs in the drug supply chain — and why it matters to advisers
Many pharmacy benefit managers promote discounts and drug rebates that may look good on paper, but often provide no transparency of true costs. This can result in employers paying much more than they should.
Greg Andrews
Corporate Synergies
Benefits Think The role of PBMs in the drug supply chain — and why it matters to employers
Many pharmacy benefit managers promote discounts and drug rebates that may look good on paper, but often provide no transparency of true costs. This can result in employers paying much more than they should.
Greg Andrews
Corporate Synergies
CVS e-prescription program aims to help employees pay less for medications
By tying its clinical database to physicians’ EHR systems, the drug chain hopes to avoid patient sticker shock and prescription abandonment at the point of sale.
CVS e-prescription program aims to help employees pay less for medications
By tying its clinical database to physicians’ EHR systems, the drug chain hopes to avoid patient sticker shock and prescription abandonment at the point of sale.
Will this hospital partnership bend Rx cost curve?
Three hundred large hospital systems are teaming up to control rising drug costs. But even their firepower might not be enough.
Cigna’s plan to buy Express Scripts is no boon to drug purchasers
Despite arguments to the contrary, the combination is unlikely to lower prescription costs for employers or employees.
Opioid treatment costing employers big
Addiction recovery costs are skyrocketing for companies, but employee education on drug usage can help stem the tide.
Will this hospital partnership bend Rx cost curve?
Three hundred large hospital systems are teaming up to control rising drug costs. But even their firepower might not be enough.
Aetna will pass along discounts as drug price scrutiny increases
Aetna will pass on the discounts it negotiates on prescription drugs to about 3 million of its members, in the latest move to address complaints about the cost of medicine.
Benefits Think How should advisers help small business clients control their prescription med costs?
Soaring drug prices are hammering smaller employers. Here are three ways benefit brokers can help.
Ron Goldstein
Choice Administrators
Partners turned into prey as insurers, drug plans get squeezed
The drug supply chain is being drawn even more taut, and the power of the big players even greater.
High costs driving government to take drug makers to task
White House, states calling for greater price transparency and accountability.
